642 reports of this reaction
2.9% of all GRANISETRON HYDROCHLORIDE reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for GRANISETRON HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 642 FDA adverse event reports linking GRANISETRON HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.9% of all 22,079 adverse event reports for this drug.
Patients taking GRANISETRON HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for GRANISETRON HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for GRANISETRON HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 642 FDA reports for GRANISETRON HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.9% of all adverse event reports for GRANISETRON HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking GRANISETRON HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.